Advanced thyroid cancers: new era of treatment
- 8 June 2014
- journal article
- review article
- Published by Springer Science and Business Media LLC in Medical Oncology
- Vol. 31 (7), 1-8
- https://doi.org/10.1007/s12032-014-0049-x
Abstract
Since chemotherapy has been shown to be unsuccessful in case of advanced thyroid carcinomas, the research for new therapies is fundamental. Clinical trials of many tyrosine kinase inhibitors as well as anti-angiogenic inhibitors suggest that patients with thyroid cancer could have an advantage with new target therapy. Recently, Food and Drug Administration approved two targeted therapies, vandetanib and cabozantinib for the treatment of metastatic thyroid carcinomas with acceptable outcome. We summarized the results and the toxic effects associated with these treatments reported in clinical trials. Future trials should aim at combinations of targeted agents with or without other treatment modalities to obtain a more effective result in thyroid carcinoma treatment.Keywords
This publication has 47 references indexed in Scilit:
- Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cellsEndocrine-Related Cancer, 2013
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III TrialJournal of Clinical Oncology, 2012
- Axitinib: The evidence of its potential in the treatment of advanced thyroid cancerCore Evidence, 2009
- Phase II Trial of Sorafenib in Metastatic Thyroid CancerJournal of Clinical Oncology, 2009
- Lack of Therapeutic Effect of the Histone Deacetylase Inhibitor Vorinostat in Patients with Metastatic Radioiodine-Refractory Thyroid CarcinomaJournal of Clinical Endocrinology & Metabolism, 2009
- Phase II Trial of Sorafenib in Advanced Thyroid CancerJournal of Clinical Oncology, 2008
- Dendritic Cell Vaccination with Xenogenic Polypeptide Hormone Induces Tumor Rejection in Neuroendocrine CancerClinical Cancer Research, 2008
- Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical ResultsJournal of Clinical Oncology, 2005
- Inhibition of Heat Shock Protein 90, a Novel RET/PTC1-associated Protein, Increases Radioiodide Accumulation in Thyroid CellsOnline Journal of Public Health Informatics, 2004
- Medullary thyroid carcinomaClinical Endocrinology, 2004